SUPPLEMENTAL MATERIAL
|
|
- Frederick Knight
- 6 years ago
- Views:
Transcription
1 SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments 9 Figure A1. Forest plot of LDL-C relative risk ratios 10 Figure A2. Forest plot of non-hdl-c relative risk ratios 11 Figure A3. Forest plot of relative apob risk ratios 12 Figure A4. Log apob RRR log non-hdl-c RRR forest plot 13 Figure A5. Log non-hdl-c RRR log LDL-C RRR forest plot 14 Figure A6. Log apob RRR log LDL-C RRR forest plot 15 Figure A7. Subgroup analyses by study attributes 16 Figure A8. Selection bias assessments: funnel plots of precision by difference in log relative risk ratios Note: Citations throughout this appendix refer to the reference list of the main article. 1
2 Table A1. List of candidate reports by inclusion/exclusion categories #A: ERFC-identified report without the requisite non-hdl-c and apob data B: ERFC-identified study with requisite data but without published non-hdl-c and apob relative risk ratios (RRRs) C: ERFC-identified report with published RRRs not included in ERFC meta-analysis D: Reports from ERFC-cited studies included in both analyses E: Reports from studies not cited by ERFC with RRRs F: Reports not cited by ERFC without RRRs 2 Ref # meta-analyses Study citation 1 A Neither *Air Force/Texas Coronary Atherosclerosis Prevention Study Circulation 2000; 101(5): A Neither *Antihypertensive and Lipid-Lowering to prevent Heart Attacks JAMA 2002; 288(23): A Neither *British Regional Heart Study BMJ 1989; 298(6679): A Neither *British Women's Heart and Health Study J Epidemiol Community Health 2003; 57(2): A Neither *Busselton population health J Epidemiol Community Health 1997; 51(5): A Neither *Caerphilly and Speedwell Collaborative Heart Disease Br Heart J 1992; 68(1): A Neither *Cardiovascular Health Study J Am Geriatr Soc 2004; 52(10): A Neither *Edinburgh Artery Study Am J Epidemiol 1992; 135(4): A Neither *Epidemiologische Studie zu Chancen der Verhütung, Pharmacoepidemiol Drug Saf 2008; 17(5): A Neither *Finish Risk Cohort Study Int J Epidemiol 2000; 29(1): A Neither *Finland, Italy and Netherlands Elderly Study Eur Heart J 2001;22(7): A Neither *GOTMONICA J Intern Med 1997; 242(3): A Neither *Glostrup Study Int J Epidemiol 1991; 20(1): A Neither *Göteborg 1943 Study J Intern Med 2000; 247(1): A Neither *Honolulu Heart Program Am J Cardiol 2000; 86(4): A Neither *Hoorn Study Diabetologia 2003; 46(7): A Neither *Israeli IHD/Glucose Intolerance, Obesity, Hypertension Preventive Medicine 2005; 41(1): A Neither *Japanese Am J Epidemiol 2001; 153(5): A Neither *Lower Extremity Arterial Disease Event Reduction Trial Curr Control Trials Cardiovasc Med 2001; 2(4): A Neither *Multiple Risk Factor Intervention Trial 1 Am J Cardiol 1986; 57(8): A Neither *Northwick Park Heart Study II Atherosclerosis 2005; 181(1): *Report cited by ERFC as providing data on triglycerides, HDL-C and non-hdl-c, and other risk factors
3 Table A1. List of candidate reports by inclusion/exclusion categories #A: ERFC-identified report without the requisite non-hdl-c and apob data B: ERFC-identified study with requisite data but without published non-hdl-c and apob relative risk ratios (RRRs) C: ERFC-identified report with published RRRs not included in ERFC meta-analysis D: Reports from ERFC-cited studies included in both analyses E: Reports from studies not cited by ERFC with RRRs F: Reports not cited by ERFC without RRRs 3 Ref # meta-analyses Study citation 22 A Neither *Population Study of Women in Göteborg, Sweden Circulation 2004; 109(5): A Neither *Progetto CUORE Eur J Cardiovasc Prev Rehabil 2006; 13(4): A Neither *Rancho Bernardo Study Am J Cardiol 2003; 91(11): A Neither *Reykjavik Study J Cardiovasc Risk 2002; 9(2): A Neither *Risk Factors and Life Expectancy Pooling Project Eur J Epidemiol 1993; 9(5): A Neither *Scottish Heart Health Extended Cohort Heart 2007; 93(2): A Neither *Established Populations for Epidemiologic Study of Elderly Aging (Milano ) 1993; 5(1): A Neither *Tromsø Study Lancet 1977; 1(8019): A Neither *West of Scotland Coronary Prevention Study Circulation 1998; 97(15): A Neither *Yao city Japan J Clin Epidemiol 1994; 47(9): A Neither *Zaragosa study BMC Public Health 2006; 6: A Neither *Zutphen Elderly Study Am J Epidemiol 1996; 143(2): B ERFC *Atherosclerosis Risk in Communities Study Circulation 104(10): B ERFC *BUPA Study Lancet. 1994;343: B ERFC *Bruneck Study Arterioscler Thromb Vasc Biol 1999; 19(6): B ERFC *Cardiovascular Study in the Elderly J Hum Hypertens 1998; 12(9): B ERFC *Diet and Risk of Cardiovascular Disease in Spain Annals of Nutrition and Metabolism 2000; 44(3):10 39 B ERFC *Dubbo Study of the Elderly Am J Cardiol 2002; 89(1): B ERFC *EPIC Norfolk Study Ann Intern Med 2007; 146(9): B ERFC *Göttingen Risk Incidence and Prevalence Study Atherosclerosis 1997; 129(2): B ERFC *Kuopio Ischaemic Heart Disease Study Circulation 1991; 84(1): *Report cited by ERFC as providing data on triglycerides, HDL-C and non-hdl-c, and other risk factors
4 Table A1. List of candidate reports by inclusion/exclusion categories #A: ERFC-identified report without the requisite non-hdl-c and apob data B: ERFC-identified study with requisite data but without published non-hdl-c and apob relative risk ratios (RRRs) C: ERFC-identified report with published RRRs not included in ERFC meta-analysis D: Reports from ERFC-cited studies included in both analyses E: Reports from studies not cited by ERFC with RRRs F: Reports not cited by ERFC without RRRs 4 Ref # meta-analyses Study citation 43 B ERFC *National Health and Nutrition Examination Survey III Am J Cardiol 2000; 86(3): B ERFC *Prospective Cardiovascular Münster Study Am J Cardiol 1992; 70(7): B ERFC *Prospective Epidemiological Study of Myocardial Infarction Arterioscler Thromb Vasc Biol 2002; 22(7): B ERFC *Prospective Study of Pravastatin in the Elderly at Risk Circulation 2005; 112(20): B ERFC *Quebec Cardiovascular Study Atherosclerosis 2000; 153(2): B ERFC *Strong Heart Study Diabetes 1992; 41 Suppl 2:4-11.: B ERFC *Turkish Adult Risk Factor Study J Epidemiol Community Health 1992; 46(5): B ERFC *Uppsala Arterioscler Thromb Vasc Biol 2006; 26(2): B ERFC *VIP/MONICA J Intern Med 1998; 244(5): B ERFC *Whitehall II Study Arterioscler Thromb Vasc Biol 2008; 28(8): C Current *Framingham Offspring Study JAMA. 2007;298: D ERFC *Copenhagen City Heart Study JAMA 2007; 298(3): D Current Copenhagen City Heart Study Arterioscler Thromb Vasc Biol. 2007;27: D Both *Nurses Health Study (11) Circulation.2004;110: D ERFC *Women s Health Study (15) JAMA. 2005;294: D Current Women s Health Study (12) Circulation. 2009;119: E Current Apolipoprotein Related Mortality Risk Study (21) J Intern Med. 2008;264: E Current Casale Monferrato Study (19) Diabetologia. 2006;49: E Current Chin-Shan Cohort (20) J Lipid Res. 2007;48: E Current Health Professionals Follow-up Study (16) Diabetes Care. 2004;27: E Current Health Professionals Follow-up Study (18) Circulation. 2005;1112: *Report cited by ERFC as providing data on triglycerides, HDL-C and non-hdl-c, and other risk factors
5 Table A1. List of candidate reports by inclusion/exclusion categories #A: ERFC-identified report without the requisite non-hdl-c and apob data B: ERFC-identified study with requisite data but without published non-hdl-c and apob relative risk ratios (RRRs) C: ERFC-identified report with published RRRs not included in ERFC meta-analysis D: Reports from ERFC-cited studies included in both analyses E: Reports from studies not cited by ERFC with RRRs F: Reports not cited by ERFC without RRRs 5 Ref # meta-analyses Study citation 64 E Current INTERHEART Study (22) Lancet 2008; 372: E Current International Studies of Infarct Survival (23) Euro Heart J (2009) 30, E Current Monitoring of Trends and Determinants in CVD (17) EurHeart J. 2005;26: F Neither 4S Placebo Wing clinical trial Circulation. 1998;97: F Neither Air Force/Texas Coronary Atherosclerosis Prevention Study Circulation. 2000;101: F Neither Angina Prognosis Study in Stockholm Atherosclerosis. 1997;135: F Neither ApoB and Type 1 Diabetes J Immunol Methods. 2006;260: F Neither Apolipoprotein Related Mortality Risk Study Clin Chem Lab Med 2004; 42: F Neither Apolipoprotein Related Mortality Risk Study Lancet. 2001;358: F Neither Apolipoprotein Related Mortality Risk Study Lancet. 2003;361: F Neither Bezafibrate Coronary Atherosclerosis Intervention Trial J Am Coll Cardiol. 1998;32: F Neither Bugalusu Heart Study Pediatrics. 2008;121: F Neither Caerphilly Prospective Study Eur J Clin Invest 2000; 30: F Neither Cardiovascular Health Study Arterioscler Thromb Vasc Biol.2002;22: F Neither Cardiovascular risk in Young Finns Study J Am CollCardiol. 2008;1: F Neither Diabetes Atherosclerosis Intervention Study Circulation. 2003;107: F Neither Dubbo Study of the Elderly Atherosclerosis 2001; 159: F Neither EPIC Norfolk Study J Am Coll Cardiol.2007;49: F Neither Eastern Finland Heart Survey Am J Cardiol. 1985;56: F Neither Fenofibrate Intervention and Event Lowering in Diabetes Diabetologia : F Neither Framingham Offspring Study J Clin Lipidol. 2007;1: *Report cited by ERFC as providing data on triglycerides, HDL-C and non-hdl-c, and other risk factors
6 Table A1. List of candidate reports by inclusion/exclusion categories #A: ERFC-identified report without the requisite non-hdl-c and apob data B: ERFC-identified study with requisite data but without published non-hdl-c and apob relative risk ratios (RRRs) C: ERFC-identified report with published RRRs not included in ERFC meta-analysis D: Reports from ERFC-cited studies included in both analyses E: Reports from studies not cited by ERFC with RRRs F: Reports not cited by ERFC without RRRs 6 Ref # meta-analyses Study citation 85 F Neither Glostrup Study Atherosclerosis 1997; 132: F Neither Guernsey Atherosclerosis 1992; 92: F Neither Incremental Decrease in End points Through Aggressive Lipidlowering Ann Med. 2008: F Neither Kuopio Ischaemic Heart Disease Study Circulation 1992; 86: F Neither Kuopio Ischaemic Heart Disease Study Arterioscler Thromb Vasc Biol 1999; 19: F Neither Leiden Heart Study. Arterioscler Thromb Vasc Biol. 2000;20: F Neither Long-term Intervention with Pravastatin in Ischaemic Disease Circulation. 2002;105: F Neither Monitoring of Trends and Determinants in CVD Eur Heart J 2005;26: F Neither National Health and Nutrition Examination Survey Am J Cardiol. 2006;98: F Neither Northwick Park Heart Study Arterioscler Thromb Vasc Biol.2002;22: F Neither Quebec Cardiovascular Study Arterioscler Thromb Vasc Biol 2005; 25: F Neither Quebec Cardiovascular Study Circulation. 1996;94: F Neither Quebec Cardiovascular Study Am J Cardiol. 2006;97: F Neither Reykjavik Study Am J Cardiol 1992; 69: F Neither Simon et al Atherosclerosis.2005;179: F Neither TEKHARF Survey Anadolu Kardiyol Derg. 2007;2: F Neither THROMBO Metabolic Syndrome Atherosclerosis. 2004;177: F Neither TNT/IDEAL Circulation. 2008; 117: F Neither Thrombosis Prevention Trial Circulation. 1999;99: F Neither U.S. Physicians Health Study N Engl J Med 1991; 325: *Report cited by ERFC as providing data on triglycerides, HDL-C and non-hdl-c, and other risk factors
7 Table A1. List of candidate reports by inclusion/exclusion categories #A: ERFC-identified report without the requisite non-hdl-c and apob data B: ERFC-identified study with requisite data but without published non-hdl-c and apob relative risk ratios (RRRs) C: ERFC-identified report with published RRRs not included in ERFC meta-analysis D: Reports from ERFC-cited studies included in both analyses E: Reports from studies not cited by ERFC with RRRs F: Reports not cited by ERFC without RRRs 7 Ref # meta-analyses Study citation 105 F Neither Uppsala Longitudinal Study of Adult Men Am Heart J 2004; 148: F Neither VA_HIT Circulation. 2006;113: F Neither Women s Health Study Circulation.2002;106: *Report cited by ERFC as providing data on triglycerides, HDL-C and non-hdl-c, and other risk factors
8 Table A2. List of covariates/model adjustments Study abbreviation Health Professionals (16) Nurses' Health(11) MONICA/KORA(17) Health Professionals(18) Women's Health(15) Casale Monferrato(19) Copenhagen Heart(13) Chin-Shan Cohort(20) Fram Offspring (10) AMORIS(21) INTERHEART(22) Women's Health(12) ISIS(23) ADJUSTMENTS age, BMI, family history of MI, physical activity, smoking (never, past, or current), alcohol consumption, fasting status, history of hypertension, aspirin use, HbA1c age, smoking, fasting status, CRP, homocysteine, BMI, family history, hypertension, diabetes, hormone use, physical activity, alcohol intake, blood draw parameters age, diabetes, regular smoking, BMI, alcohol intake age, smoking, blood draw, BMI, parent MI < 60, hypertension, alcohol intake, physical activity age, Framingham BP category, BMI, diabetes, current smoking age, sex, hypertension, smoking, CHD, AER, fibrinogen, cumulative average HbA1c, referring physician age age group, gender, BMI, smoking, alcohol, marital status, education, occupation, exercise, family CHD history, hypertension, diabetes age, SBP, antihypertensive treatment, diabetes, smoking age sex age, sex, smoking, geographic region age, randomized treatment assignment, smoking status, postmenopausal hormone use, blood pressure, diabetes, BMI age, sex, smoking, BMI 8
9 LDL C relative risk ratio (RRR) Study name Subgroup within study Statistics for each study Hazard ratio and 95% CI Hazard Lower Upper ratio limit limit Z-Value p-value Health Professionals (16) men Nurses' Health(11) women Health Professionals (18) men Casale Monferrato(19) pooled Copenhagen Heart(13) men Copenhagen Heart(13) women Chin-Shan Cohort(20) pooled Fram Offspring (10) men Fram Offspring (10) women AMORIS(21) pooled INTERHEART(22) pooled Women's Health(12) women ISIS(23) pooled Overall anti-atherogenic atherogenic Meta Analysis Figure A1. Forest plot of LDL-C relative risk ratios among 13 studies in 11 reports with both apob and non-hdl-c relative risk ratios. The relative risk ratio was significantly greater (p<0.05) than 1.0 within 9 of the 13 studies and highly significant (p<0.001) overall. Heterogeneity was also highly significant (p <0.001). 9
10 Non-HDL C relative risk ratio (RRR) Study name Subgroup within study Statistics for each study Hazard ratio and 95% CI Hazard Lower Upper ratio limit limit Z-Value p-value Health Professionals (16) men Nurses' Health(11) women MONICA/KORA(17) men MONICA/KORA(17) women Health Professionals (18) men Casale Monferrato(19) pooled Copenhagen Heart(13) men Copenhagen Heart(13) women Chin-Shan Cohort(20) pooled Fram Offspring (10) men Fram Offspring (10) women AMORIS(21) pooled INTERHEART(22) pooled Women's Health(12) women ISIS(23) pooled Overall anti-atherogenic atherogenic Meta Analysis Figure A2. Forest plot of non-hdl-c relative risk ratios among 15 independent studies in 12 reports with both apob and non-hdl-c relative risk ratios. The relative risk ratio was significantly greater (p<0.05) than 1.0 within 12 of the 15 studies and highly significant (p<0.001) overall. Heterogeneity was also highly significant (p <0.001). 10
11 ApoB relative risk ratio (RRR) Study name Subgroup within study Statistics for each study Hazard ratio and 95% CI Hazard Lower Upper ratio limit limit Z-Value p-value Health Professionals (16) men Nurses' Health(11) women MONICA/KORA(17) men MONICA/KORA(17) women Health Professionals (18) men Casale Monferrato(19) pooled Copenhagen Heart(13) men Copenhagen Heart(13) women Chin-Shan Cohort(20) pooled Fram Offspring (10) men Fram Offspring (10) women AMORIS(21) pooled INTERHEART(22) pooled Women's Health(12) women ISIS(23) pooled Overall anti-atherogenic atherogenic Meta Analysis Figure A3. Forest plot of apob relative risk ratios among 12 independent published reports with both apob and non-hdl-c relative risk ratios. The relative risk ratio is significantly greater (p<0.05) than 1.0 within each study and highly significant (p<0.001) overall. Heterogeneity was also highly significant (p <0.001). 11
12 Log apob relative risk ratio (RRR) - non-hdl C RRR Study name Subgroup within study Statistics for each study Point estimate and 95% CI Point Standard Lower Upper estimate error Variance limit limit Z-Value p-value Health Professionals (16) men Nurses' Health(11) women MONICA/KORA(10) men MONICA/KORA(10) women Health Professionals(18) men Casale Monferrato(19) pooled Copenhagen Heart(13) men Copenhagen Heart(13) women Chin-Shan Cohort(20) pooled Fram Offspring (10) men Fram Offspring (10) women AMORIS(21) pooled INTERHEART(22) pooled Women's Health(12) women ISIS(23) pooled Overall non-hdl C <- favors->apob Meta Analysis Figure A4. Log apob RRR log non-hdl-c RRR forest plot of 12 independent published studies with both apob and non-hdl-c vascular risk associations. This analysis counts the three reports stratified by sex as six separate studies and excludes a Women s Health Study report(12) based on a subset of the later Women s Health Study report (19). The overall mean difference in log relative risk ratios (95% confidence interval) of (0.024, 0.087) equates to a 5.7% (2.4%, 9.1%), p<0.001, advantage favoring apob over non-hdl-c as a marker of atherogenic risk
13 Log non-hdl C relative risk ratio (RRR) - log LDL C RRR Study name Subgroup within study Statistics for each study Point estimate and 95% CI Point Standard Lower Upper estimate error Variance limit limit Z-Value p-value Health Professionals(16) men Nurses' Health(11) women Health Professionals(18) men Casale Monferrato(19) pooled Copenhagen Heart(13) men Copenhagen Heart(13) women Chin-Shan Cohort(20) pooled Fram Offspring (10) men Fram Offspring (10) women AMORIS(21) pooled INTERHEART(22) pooled Women's Health(12) women ISIS(23) pooled Overall LDL C <- favors -> non-hdl C Meta Analysis Figure A5. Log non-hdl-c RRR log LDL-C RRR forest plot of the 11 independent published reports with both non-hdl-c and LDL-C relative risk ratios among the 13 published reports with both apob and non-hdl-c relative risk ratios. This analysis counts the two reports stratified by sex as four separate studies and excludes a Women s Health Study report(12) based on a subset of the later Women s Health Study report (19). The overall mean difference in log relative risk ratios (95% confidence interval) of (0.009, 0.091) equates to a 5.1% (0.9%, 9.5%), p=0.017, advantage favoring non-hdl-c over LDL-C as a marker of atherogenic risk. 13
14 Log apob relative risk ratio (RRR) - log LDL C RRR Study name Subgroup within study Statistics for each study Point estimate and 95% CI Point Standard Lower Upper estimate error Variance limit limit Z-Value p-value Health Professionals (16) men Nurses' Health(11) women Health Professionals(18) men Casale Monferrato(19) pooled Copenhagen Heart(13) men Copenhagen Heart(13) women Chin-Shan Cohort(20) pooled Fram Offspring (10) men Fram Offspring (10) women AMORIS(21) pooled INTERHEART(22) pooled Women's Health(12) women ISIS(23) pooled Overall LDL C <- favors -> apob C Meta Analysis Figure A6. Log apob RRR log LDL-C RRR forest plot of the 11 independent published reports with both apob and LDL-C relative risk ratios among the 13 reports with both apob and non-hdl-c relative risk ratios. This analysis counts the two reports stratified by sex as four separate studies and excludes a Women s Health Study report(12) based on a subset of the later Women s health Study report (19). The overall mean difference in log relative risk ratios (95% confidence interval) of = (0.085, 0.154) = equates to a 12.7% (8.9%, 16.6%), p<0.001, advantage apob over LDL-C as a marker of atherogenic risk. 14
15 Figure A7. Subgroup analyses by study attributes. The p-values for each section indicate result from testing equality of the difference between the apob and non-hdl-c log relative risk ratios across the section s subgroups. Assay well documented reflects the authors judgment regarding reported assurances re: assay/specimen quality. Mean of subgroup comparison versus 0%: *p<0.05, ** p<0.01, ***p<0.001 % 15
16 A 500 B C 200 A. ApoB versus NonHDL-C B. NonHDL-C versus LDL-C C. ApoB versus LDL-C Precision (1/standard error) (0.024, 0.087) (0.016, 0.078) (0.009, 0.091) (0.005, 0.084) (0.085, 0.154) (0.024, 0.093) Figure A8. Selection bias assessments: funnel plots of precision by difference in log relative risk ratios. The empty circles represent the observed studies while the empty diamonds represents the overall random effects means and 95% confidence intervals of the observed studies. If smaller studies were not published owning to non-significant findings, one would expect the distribution of empty circles to be skewed to the right. The black filled circles represent studies imputed to balance the distribution around the overall estimate and the black diamonds represent overall average adjusted by including the imputed studies. After adjustment each overall difference remains statistically significant. 16
Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationUniversity of Bristol - Explore Bristol Research
The Global BMI Mortality Collaboration, & Bansal, N. (06). Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 39 prospective studies in four continents. Lancet, 3(006),
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationSupplementary Online Content
Supplementary Online Content Gregson J, Kaptoge S, Bolton T, et al; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. Published online
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationEUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium
EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV GUY DE BACKER Ghent University,Belgium ESC Congress 2012, aug.25-29th, Munich, Germany ESC Congress 2012, aug.25-29th, Munich,
More informationHigh-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationProven and Proposed Cardiovascular Benefits of Soyfoods
Proven and Proposed Cardiovascular Benefits of Soyfoods Mark Messina, PhD, MS Soy Nutrition Institute Loma Linda University Nutrition Matters, Inc. markjohnmessina@gmail.com Alpro Foundation 20 years symposium
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationTraditional Asian Soyfoods. Proven and Proposed Cardiovascular Benefits of Soyfoods. Reduction (%) in CHD Mortality in Eastern Finland ( )
Proven and Proposed Cardiovascular Benefits of Soyfoods Mark Messina, PhD, MS Soy Nutrition Institute Loma Linda University Nutrition Matters, Inc. markjohnmessina@gmail.com 1000 80 20 60 40 40 60 20 80
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationThe Whitehall II study originally comprised 10,308 (3413 women) individuals who, at
Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.
More informationAdvanced IPD meta-analysis methods for observational studies
Advanced IPD meta-analysis methods for observational studies Simon Thompson University of Cambridge, UK Part 4 IBC Victoria, July 2016 1 Outline of talk Usual measures of association (e.g. hazard ratios)
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More information2/17/2015. ApoB Versus Non-HDL Cholesterol And the Winner Is. Braunwald10 th Edition Chapter 45 J GenestPA Libby. Emerging Risk Factor Collaboration
ApoB Versus Non-HDL Cholesterol And the Winner Is Allan Sniderman McGill University Braunwald10 th Edition Chapter 45 J GenestPA Libby The clinical usefulness of apolipoprotein levels has stirred debate
More informationApolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationLIPOPROTEIN PROFILING
LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationPrevention of Cardiovasular Diseases
Role and Significance of In-Vitro-Diagnostics in the Healthcare Systems of the Future Prevention of Cardiovasular Diseases Michael Walter Charité University Medicine, Berlin & Unfallkrankenhaus Berlin
More informationAppendix: Definition of variables in the studies included in the meta-analysis
Appendix: Definition of variables in the studies included in the meta-analysis Belonging to the article: Bogers RP, BemelmansWJE, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, van Dam RM, Hu FB, Visscher
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationBiomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease
Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More information김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과
치매예방을위한만성질환관리전략 김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과 A sharp rise in the death rate from Alzheimer s disease Ivan Casserly & Eric Topol, Lancet 2004 Potential for primary prevention of Alzheimer s disease Alzheimer
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationI t is well established that non-insulin dependent diabetes is
1398 CARDIOVASCULAR MEDICINE Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease S G Wannamethee, A G Shaper, L Lennon... See end of article
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Page: 1 of 35 Last Review Status/Date: December 2014 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease
Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationEpidemiological studies indicate that a parental or family
Maternal and Paternal History of Myocardial Infarction and Risk of Cardiovascular Disease in Men and Women Howard D. Sesso, ScD, MPH; I-Min Lee, MBBS, ScD; J. Michael Gaziano, MD, MPH; Kathryn M. Rexrode,
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationThe apob/apoa-i ratio: a strong, new risk factor for. cardiovascular disease and a target for lipidlowering
Journal of Internal Medicine 2006; 259: 493 519 doi:10.1111/j.1365-2796.2006.01643.x SYMPOSIUM The apob/apoa-i ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPopulation models of health impact of combination polypharmacy
Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067
More informationSupplementary Online Content
Supplementary Online Content Åsvold BO, Vatten LJ, Bjøro T, et al; Thyroid Studies Collaboration. Thyroid function within the normal range and risk of coronary heart disease: an individual participant
More informationDownloaded from:
Emerging Risk Factors Collaboration (inc Fletcher, AE; ) Sarwar, N; Gao, P; Seshasai, SR; Gobin, R; Kaptoge, S; Di Angelantonio, E; Ingelsson, E; Lawlor, DA; Selvin, E; Stampfer, M; Stehouwer, CD; Lewington,
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk
ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol
More informationSupplementary Online Content
Supplementary Online Content Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9768.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationCRP for the Clinician
CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationTHE CRITICAL ROLE OF NURSES. Helping patients take control of their LDL-C to lower the risk of MI and stroke.
THE CRITICAL ROLE OF NURSES Helping patients take control of their LDL-C to lower the risk of MI and stroke. WHEN IT COMES TO REDUCING PATIENTS HIGH CHOLESTEROL, NURSES PLAY A KEY ROLE Many patients may
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More information